G-TAC – M3 (a Sony Company) and Pathway Genomics Partner to Market CancerIntercept™, BRCATrue® and Fitness Genetic Tests in Japan

TOKYO — (BUSINESS WIRE) — G-TAC Co., Ltd. and M3, Inc. (an associated company of SONY) announced a strategic business partnership with Pathway Genomics to market fourteen tests including CancerIntercept™, BRCATrue®, PathwayFit®, SkinFit™ and other genetic tests through G-TAC’s genomics network of over 20,000 physicians in Japan.

Pathway Genomics Provides Updates for CancerIntercept™ Detect Clinical Program

SAN DIEGO May 26, 2016  – Pathway Genomics today provided an update on the clinical development program for its liquid biopsy, CancerIntercept™ Detect, a non-invasive screening test for detection of mutations that have been associated with cancer. Pathway Genomics researchers have initiated a clinical trial for the detection of thyroid cancer – the company’s third ongoing study for the technology. The company also announced the publication of two abstracts in the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting Proceedings.

“The initiation of the thyroid study is an important step in our clinical development program for CancerIntercept and will help increase our understanding of its potential as a biomarker for the early detection of thyroid cancer,” said Glenn Braunstein, M.D., chief medical officer of Pathway Genomics. “We are in the process of initiating additional disease specific studies for early cancer detection in high risk patients, including a study in lung cancer, and will present and publish the data in the appropriate forums.”

Pathway Genomics Debuts First Genomic Wellness App Powered by IBM Watson

LAS VEGAS 7 January 2016 – Pathway Genomics and IBM (NYSE: IBM) today unveiled at the Digital Health Summit at CES 2016 the closed-alpha release of Pathway Genomics OME™ app, powered by Watson. The Pathway Genomics OME app merges cognitive computing and deep learning with precision medicine and genetics to enable Pathway Genomics to provide consumers with personalized wellness information.

This alpha version of the app incorporates information from Pathway’s “FIT” Test — a wellness-based diet, exercise, and metabolism report compiled with information from the users unique genetic traits, as well as their health habits, data from GPS and wearable health monitors in addition to information from the users Apple HealthKit. Future versions of Pathway’s OME will enable users to opt-in to include electronic health records, insurance information, and additional datasets that will enable OME to provide precise and actionable wellness recommendations.

Pathway Genomics Corporation Raises Over $40 Million In Series E Financing

SAN DIEGO, CA – January 5, 2016 – Pathway Genomics Corporation, a global precision medicine company with mobile health solutions, today announced it has successfully raised over $40 million in a Series E financing.

This brings the total investment into Pathway Genomics to over $130 million. Investors in this round of funding include IBM Watson, Pathway’s partner in the development of a mobile health application using artificial intelligence to provide personalized health and wellness guidance.

Pathway Genomics Announces Definitive Settlement With United States

Pathway Genomics has reached a settlement with the United States Department of Justice. Pathway admits no wrongdoing as part of the settlement and is neither an admission of liability or wrongdoing by the Company, nor a concession by the United States that its claims are not well founded.

Pathway Genomics’ Response to FDA Letter on CancerIntercept™ Detect

Pathway Genomics greatly respects and shares the FDA’s concerns about patient safety. We have received a letter from FDA, dated September 21, 2015, requesting certain information regarding the Pathway Genomics CancerIntercept™ Detect testing service. We are carefully considering the concerns of the FDA as stated in their letter, and we will be responding to that letter. We assure that there is physician involvement in the ordering, review and follow-up of CancerIntercept™ testing. We believe that CancerIntercept™ Detect is a laboratory developed test and, as a CLIA and CAP certified clinical laboratory, we are offering it as such. While Pathway Genomics is involved in educating and marketing the tests to physicians and consumers, we do not believe this is a direct-to-consumer model. We believe we have performed appropriate validation of the test as a laboratory developed test, and we are in the process of performing additional studies.

Former Administrator of the U.S. Small Business Administration Hector Barreto Joins Pathway Genomics’ Strategic Advisory Board

Hector Barreto

San Diego, CA – August 18, 2015Pathway Genomics, a global precision medical diagnostics company with mobile health applications designed to empower physicians and their patients to take control of their health and wellness, has announced today that Hector Barreto, the 21st Administrator of the U.S. Small Business Administration, has joined the Company’s Strategic Advisory Board.

Click to Tweet

Former United States Secretary of Commerce Barbara Franklin Joins Pathway Genomics’ Board of Directors

Barbara Frankin

Former United States Secretary of Commerce Barbara Franklin Joins Pathway Genomics’ Board of Directors


San Diego, CA – June 16, 2015Pathway Genomics Corporation, a global precision medicine company with mobile health solutions for clinical laboratory testing to empower physicians and their patients to take control of their health and wellness, announced today that the 29th U.S. Secretary of Commerce, The Honorable Barbara Franklin is joining the company’s Board of Directors.

Click to Tweet